OCTREOTIDE

Brand name:

• Sandostatin®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Novartis Pharmaceuticals Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Non-functional neuroendocrine tumours of midgut or suspected midgut origin

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (Major)

Comment:

--

Other PBAC consideration:

--

Submission received for:

July 2019 PBAC meeting

Opportunity for consumer comment:

Open 01/05/2019 and close 12/06/2019 (see PBS Website)

PBAC meeting:

Held on 10/07/2019

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

28/08/2019

Lodgement of required documentation:

19/09/2019

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 27/09/2019

Status:

Finalised

Government processes:

Commenced on 09/12/2019

Medicine listed on the PBS:

01/02/2020 (see PBS schedule)